

**RAG Rating/Status**

At risk	Red - Action date passed or revised date needed
On track	Yellow - Action on target to be completed by agreed/revised date
Complete	Green- Action complete
No longer needed	Blue - Action to be removed and/or replaced by new action

FORMAL BOARD								
Meeting Item Reference	Action Reference	Lead	Meeting Item Title	Details of action	Update on progress	Original target date	Revised target date	RAG rating/Status
<b>OPEN ACTIONS FOR REVIEW - no open actions</b>								
<b>OPEN ACTIONS - IN PROGRESS BUT NOT YET DUE</b>								
PHW 2021_11_25/317.2/2021	PHW 2021	MK	Integrated Performance and Finance Report, Month 7- Theme 3, Organisational quality and access to high quality services	DE highlighted the opportunities when reactivating screening services to consider whether the current measures used to capture performance remained appropriate or whether alternative/extra indicators could be added at this point. MK supported a review of the metrics in place currently and confirmed that he would consider this further	<b>31.3.22 Update</b> - on track as per last update  <b>27.01.22 Update</b> - Consideration of the points raised are in progress. The action is on track for the target date.	30/6/22		On track
PHW 2021_01_27/4.1/2022	PHW 2022/02	TC / HB	Chief Executive Report	JW welcomed the intention to conduct a comprehensive 'Debrief' into communication around changes to the Cervical Screening programme to identify all the learning and to secure improvements across service change processes of this kind, and asked TC to keep the Board informed as the work developed.	<b>31.3.22 Update</b> - Internal debrief underway and will report to Board for the due date	31/5/22		On track
PHW 2021_01_27/4.3/2022	PHW 2022/04	MK	Intergrated Performance Report (Month 9) - Organisational quality and access to high quality services	JR welcomed the progress in reducing backlogs and the identification of novel approaches. She asked whether the use of optometrists for low-risk diabetic eye screening was a trial that could become permanent. MK confirmed that this would be subject to evaluation and the results shared with the Board.	<b>31.3.22 Update</b> - this will be considered as outlined and reported back to Board for the due date	30/7/22		On track
<b>ACTIONS RECOMMENDED TO BE CLOSED AT 31 MARCH 2022 MEETING</b>								
PHW 2021_11_25/317.2/2021	PHW 2021	KE, DE, MM, SG (Committee Chairs)	Integrated Performance and Finance Report, Month 7- Theme 4, Improved population health and well-being	HG also confirmed the intention to continue with the themed approach set out in this report; JW asked Committee Chairs to review their Committee agendas, to ensure appropriate coverage against the themes	<b>31.3.22 Update</b> - use of the IPR is now integrated into all Committees other than Knowledge, Reserach and Information who will be doing so in 2022/23.  <b>27.01.22 Update</b> - action in progress for 2022/23 planning as well as remaining agendas for 2021/22. The topic will form part of a specific item at a joint Committee Chairs and Lead Executive meeting early March 2022.	31/3/22		Complete

PHW 2021_01_27/3/2022	PHW 2022/01	MM / NL	Pledge- Zero Tolerance to Racism	MM also expressed his thanks and proposed a role for the People and Organisational Development (POD) Committee in the monitoring process; colleagues supported this proposal.	<b>31.3.22 Update</b> - item integrated into the People & OD Committee forward plan. Proposed to close on that basis.	31/3/22		Complete
PHW 2021_01_27/4.1/2022	PHW 2022/03	SG/IB	Chief Executive Report	IB updated the Board on Public Health Wales' engagement in an antiviral drug trial. IB noted the opportunities associated with this trial to move toward more rapid trials' development in the future. SG added that the Knowledge, Research and Information Committee would explore this issue and report back to the full Board.	<b>31.3.22 Update</b> - the Knowledge, Research and Information Committee considered the item at its February meeting and will report to Board in both March and May.	31/3/22		Complete
PHW 2021_01_27/4.3/2022	PHW 2022/05	MB	Intergrated Performance Report (Month 9) - Improved population health and wellbeing	MM had commented positively on the inclusion of strategic risk assessments as part of performance reporting. He queried the reporting of risk 2 as being green/amber, given the lack of progress against a number of the actions. MB, the strategic risk owner, indicated that many actions were underway; he agreed to look at the text supplied.	<b>31.3.22 Update</b> - the action is underway as part of the wider review of strategic risks linked to the IMTP 2022-25 development. The Board agenda for 31/3/22 will consider strategic risks and fuller rreport presented to the May 2022 Board. Proposed to close on that basis.	31/3/22		Complete
PHW 2021_05_27/251.1/2021	PHW 2021	RB-W	Quality and Improvement Strategy	Progress discussions on the Quality Improvement Hub outside the meeting.	<b>31.3.22 Update</b> - work has progressed as part of the IMTP as presented to Board in March 2022. Focussed Board development session on the topic also in place for April 2022. Proposed to close on that basis.  <b>27.01.22 Update</b> - update remains valid from last meeting. The Business Executive Team considered new proposals for the theme of work on the 17 January, further details will follow to Board in due course. <b>Revised target date to March 2022 approved</b>  <b>22.11.21 Update</b> - Executive colleagues are currently working the mechanics of the hub and will update Board in due course. <b>23.9.21 Update</b> As identified in the Quality and Improvement implementation approved plan, the Improvement Hub is due to be	30/11/21 then 31/1/22 then 31/3/22		Complete

<p>PHW 2021_11_25/317.2/ 2021</p>	<p>PHW 2021</p>	<p>RB-W</p>	<p>Integrated Performance and Finance Report, Month 7- Theme 3, Organisational quality and access to high quality services</p>	<p>On risk management, RB-W reminded the Board that, following a review, the June 2021 Board meeting had reached agreement on five strategic risks, reduced to four at the September meeting, with Strategic risk 2 being redesignated as a corporate risk. A further period of reassessment was now underway, including consideration of the optimum management of risks relating to innovation and improvement. In response to a query from JW, RB-W confirmed that it would be possible to bring an update report to the January 2022 Board meeting.</p>	<p><b>31.3.22 Update</b> - strategic risks have been reviewed as part of the IMTP 2022-25 process and presented to Board in March 2022. Following the meeting the new risks will be fully developed and presented to the May 2022 Board, proposed to close on that basis.</p> <p><b>27.01.22 Update</b> - further assessment is underway and also needs to be considered with the refresh of the Long Term Strategy and risk appetite. The revised corporate risk remains in place during this period of further assessment. Further work is also underway in relation to the approach to Quality and Improvement at an organisational level which will need to inform risk management in this area.</p> <p><b>Revised target date to March 2022</b></p>	<p>27/1/22 then 31/3/22</p>		<p>Complete</p>
---	-----------------	-------------	--	---	--	-------------------------------------	--	-----------------